Buckingham Strategic Partners Ocugen, Inc. Transaction History

Buckingham Strategic Partners

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.75 - $3.1 $27,125 - $48,050	15,500 New	15,500 $28,000
Q2 2022 Aug 12, 2022	SELL	$1.83 - $3.45 $27,450 - $51,750	-15,000 Closed	0 $0
Q1 2022 May 10, 2022	BUY	$2.34 - $4.72 $2,340 - $4,720	1,000 Added 7.14%	15,000 $50,000
Q4 2021 Feb 10, 2022	BUY	$4.38 - $15.67 $61,320 - $219,380	14,000 New	14,000 $64,000

124

78.3M

535K

523K

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $167M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

Get notified when there are updates to the investment portfolio of Buckingham Strategic Partners, based on Form 13F filings with the SEC.

Stay updated on Buckingham Strategic Partners with notifications on news.